Perspectives of Rare Disease Experts on Newborn Genome Sequencing
JAMA Network Open · 08.05.2023 · 6 (5) · e2312231
DOI: 10.1001/jamanetworkopen.2023.12231 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 08.05.2023. Verfasst von Nina B Gold und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics and Metabolism, Massachusetts General Hospital for Children, Boston. Hauptthemen laut MEDLINE: Rare Diseases, Chondroitinsulfatases. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NEI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Importance Newborn genome sequencing (NBSeq) can detect infants at risk for treatable disorders currently undetected by conventional newborn screening. Despite broad stakeholder support for NBSeq, the perspectives of rare disease experts regarding which diseases should be screened have not been ascertained.
Objective
To query rare disease experts about their perspectives on NBSeq and which gene-disease pairs they consider appropriate to evaluate in apparently healthy newborns. Design, Setting, and Participants This survey study, designed between November 2, 2021, and February 11, 2022, assessed experts’ perspectives on 6 statements related to NBSeq. Experts were also asked to indicate whether they would recommend including each of 649 gene-disease pairs associated with potentially treatable conditions in NBSeq. The survey was administered between February 11 and September 23, 2022, to 386 experts, including all 144 directors of accredited medical and laboratory genetics training programs in the US. Exposures Expert perspectives on newborn screening using genome sequencing. Main Outcomes and Measures The proportion of experts indicating agreement or disagreement with each survey statement and those who selected inclusion of each gene-disease pair were tabulated. Exploratory analyses of responses by gender and age were conducted using t and χ 2 tests.
Results
Of 386 experts invited, 238 (61.7%) responded (mean [SD] age, 52.6 [12.8] years [range 27-93 years]; 126 [52.9%] women and 112 [47.1%] men). Among the experts who responded, 161 (87.9%) agreed that NBSeq for monogenic treatable disorders should be made available to all newborns; 107 (58.5%) agreed that NBSeq should include genes associated with treatable disorders, even if those conditions were low penetrance; 68 (37.2%) agreed that actionable adult-onset conditions should be sequenced in newborns to facilitate cascade testing in parents, and 51 (27.9%) agreed that NBSeq should include screening for conditions with no established therapies or management guidelines. The following 25 genes were recommended by 85% or more of the experts: OTC , G6PC , SLC37A4 , CYP11B1 , ARSB , F8 , F9 , SLC2A1 , CYP17A1 , RB1 , IDS , GUSB , DMD , GLUD1 , CYP11A1 , GALNS , CPS1 , PLPBP , ALDH7A1 , SLC26A3 , SLC25A15 , SMPD1 , GATM , SLC7A7 , and NAGS . Including these, 42 gene-disease pairs were endorsed by at least 80% of experts, and 432 genes were endorsed by at least 50% of experts. Conclusions and Relevance In this survey study, rare disease experts broadly supported NBSeq for treatable conditions and demonstrated substantial concordance regarding the inclusion of a specific subset of genes in NBSeq.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Genetics and Metabolism, Massachusetts General Hospital for Children, Boston.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- Ariadne Labs, Boston, Massachusetts.
- Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
- Geisel School of Medicine, Hanover, New Hampshire.
Förderung
- NIDDK NIH HHS
- NEI NIH HHS
- Intramural NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- NHGRI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Gold, N. B., Adelson, S. M., Shah, N., Williams, S., Bick, S. L., Zoltick, E. S., Gold, J. I., Strong, A., Ganetzky, R., Roberts, A. E., Walker, M., Holtz, A. M., Sankaran, V. G., Delmonte, O., Tan, W., Holm, I. A., Thiagarajah, J. R., Kamihara, J., Comander, J., …, & Green, R. C. (2023). Perspectives of Rare Disease Experts on Newborn Genome Sequencing. JAMA Network Open, 6(5), e2312231. https://doi.org/10.1001/jamanetworkopen.2023.12231
Vancouver
Gold NB, Adelson SM, Shah N, Williams S, Bick SL, Zoltick ES, et al. Perspectives of Rare Disease Experts on Newborn Genome Sequencing. JAMA Network Open. 2023;6(5):e2312231. doi:10.1001/jamanetworkopen.2023.12231
BibTeX
@article{Gold2023,
author = {Gold, Nina B and Adelson, Sophia M and Shah, Nidhi and Williams, Shardae and Bick, Sarah L and Zoltick, Emilie S and Gold, Jessica I and Strong, Alanna and Ganetzky, Rebecca and Roberts, Amy E and Walker, Melissa and Holtz, Alexander M and Sankaran, Vijay G and Delmonte, Ottavia and Tan, Weizhen and Holm, Ingrid A and Thiagarajah, Jay R and Kamihara, Junne and Comander, Jason and Place, Emily and Wiggs, Janey and Green, Robert C},
title = {Perspectives of Rare Disease Experts on Newborn Genome Sequencing},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {5},
pages = {e2312231},
doi = {10.1001/jamanetworkopen.2023.12231}
}
EUVIMED